INmune Bio and QCi Apply Quantum Computing to XPro Research
Oct 14, 2026
Life Sciences
Insilico Medicine and SK Biopharmaceuticals Sign $2.5 Billion AI Drug Discovery Deal
Jun 23, 2026
Insilico Medicine and SK Biopharmaceuticals have entered a research and development collaboration worth up to $2.5 billion to develop drug candidates for neuroimmune disorders using Insilico’s AI platform.
Insilico Medicine and SK Biopharmaceuticals have entered a research and development collaboration to discover drug candidates for neuroimmune disorders, announced in a press release. The agreement, revealed at the BIO 2026 International Convention, has a potential total value exceeding 2.5 billion dollars.
Under the partnership, Insilico will use its Pharma.AI platform for target validation, generative chemistry, and molecule optimization. SK Biopharmaceuticals will oversee late-stage development and commercialization of resulting therapies targeting neuroimmune conditions affecting the central nervous system.
Insilico will receive up to 18 million dollars in upfront and near-term milestone payments, with additional payments tied to development, regulatory, and commercial milestones. The company will also earn single-digit royalties on net sales once products reach the market.
The collaboration aims to accelerate the discovery of therapies for neuroinflammatory, neurodegenerative, and rare neurological disorders by combining Insilico’s AI-based research capabilities with SK Biopharmaceuticals’ clinical expertise.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Oct 16 RapidCanvas Raises $29 Million to Expand Enterprise AI Platform Oct 16 KBRA Rated Anthropic BB+ Before $35 Billion Chip Financing Oct 16 Goodweek Raises $12 Million for AI Management Platform Oct 16 Intuit Agrees to Acquire AI Billing Startup Sequence for Reported $200 Million Oct 16 Matters Raises $5 Million to Build AI Consumer BankMore from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354
Sep 30, 2026
Biotech
Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion
Oct 15, 2026
Biotech
Linearis Joins Two Canadian AI Health Data Projects
Sep 16, 2026
Healthcare
AbbVie Partners With Valkai on AI Tools for Clinical Development
Sep 29, 2026
Biotech
Lunit and Discovery Life Sciences Partner on AI Tissue Analysis
Oct 12, 2026
Biotech
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.